Sign in

Paul A. Seid

Director at BGSF
Board

About Paul A. Seid

Independent director of BGSF; age 77; director since 2014. Serves on BGSF’s Compensation Committee and the Nominating & Corporate Governance Committee. Background includes board service at BioVentrix (since 2010), CEO of RST Automation (since 2013), and President of Strategic Data Marketing (past 18 years). Education: BA in Political Science, Queen’s College (CUNY), 1968; founded/bought/sold over twenty companies across multiple geographies .

Past Roles

OrganizationRoleTenureCommittees/Impact
RST AutomationChief Executive OfficerSince 2013Executive leadership of medical robotics maker
Strategic Data MarketingPresidentPast 18 yearsResearch/data collection operator
Various companies (Asia, Europe, North & South America)Founder/Buyer/SellerNot disclosedBuilt and exited >20 companies

External Roles

OrganizationRoleTenureNotes
BioVentrix (medical device company)DirectorSince 2010Board service; company described as medical device
RST AutomationCEOSince 2013Maker of hospital robotic devices
Strategic Data MarketingPresidentPast 18 yearsResearch/data collection company
Other boards/consultingVariousNot disclosedNumerous board and consulting positions (not specified)

Board Governance

  • Independence: Board determined Paul A. Seid is independent under NYSE rules, alongside other listed directors .
  • Committee memberships: Compensation Committee (member); Nominating & Corporate Governance Committee (member) .
  • Committee chair roles: None; Compensation Committee chaired by Richard L. Baum Jr. ; Nominating & Corporate Governance Committee chaired by Richard L. Baum Jr. .
  • Board & committee activity/attendance:
    • Board met 5 times in 2024; each director attended all Board meetings and at least 75% of applicable committee meetings during service .
    • Audit Committee held 4 meetings in 2024 .
    • Compensation Committee held 1 meeting in 2024 .
    • Nominating & Corporate Governance Committee held 1 meeting in 2024 .
  • Annual meeting attendance: All seven directors attended the 2024 annual meeting .
  • Board leadership & risk oversight: Chair is Douglas E. Hailey; Board separates Chair/CEO roles and delegates risk oversight primarily to the Audit Committee .

Fixed Compensation

Component (FY 2024)Amount (USD)Notes
Annual Board retainer$45,000Non-management director cash retainer
Audit Committee retainer$0Audit member retainer is $5,000; Seid not on Audit Committee
Compensation Committee fee$0No committee fee disclosed beyond audit
Nominating & Corporate Governance Committee fee$0No committee fee disclosed beyond audit
Meeting feesNot disclosedNo meeting fee program disclosed in proxy

Performance Compensation

Award Type (FY 2024)ASC 718 Fair Value (USD)Plan/AdministrationGrant/Terms
Stock awards$70,925Administered by Compensation Committee; stock plans include 2013 LTIP, 2020 ESPP
Option awards$14,417Administered by Compensation Committee; values per ASC 718
  • No performance-based metrics for director equity awards are described; director compensation is presented as cash retainers, stock awards, and options (no PSUs/metric disclosures) .
  • Clawback policy exists for executive compensation; general governance policies and charters are adopted (Code of Ethics, insider trading, corporate governance guidelines) .

Other Directorships & Interlocks

CompanyPublic/Private (as disclosed)RoleCommittee Roles
BioVentrix (medical device company)Not specifiedDirectorNot disclosed
RST AutomationNot specifiedCEON/A
Strategic Data MarketingNot specifiedPresidentN/A
Other boards/consultingNot specifiedVariousNot disclosed

Expertise & Qualifications

  • Industry/operator experience: Founder/buyer/seller across >20 companies globally; leadership in med-tech and data/market research .
  • Governance: Long-serving independent director of BGSF with committee experience (Compensation; Nominating & Corporate Governance) .
  • Financial oversight exposure: Compensation Committee member; Board’s governance framework includes Audit oversight of related-party transactions .
  • Education: BA Political Science, Queen’s College (CUNY), 1968 .

Equity Ownership

As of Feb 5, 2025Shares Beneficially OwnedIncluded Exercisable Options (≤60 days)Included Unvested Restricted StockPercent of OutstandingShares Outstanding Reference
Paul A. Seid129,19015,69410,0931.2%11,077,007 shares outstanding
  • Beneficial ownership includes options exercisable within 60 days and unvested restricted common stock as noted .
  • Section 16(a) compliance: Company believes all required ownership reports for FY 2024 were timely filed .

Governance Assessment

  • Positives:
    • Independent status and active committee membership (Compensation; Nominating & Corporate Governance) support board effectiveness .
    • Strong attendance: all directors attended all Board meetings in 2024; committee participation thresholds met; presence at annual meeting supports engagement .
    • Meaningful equity exposure via stock and option awards and direct ownership (1.2% of shares), indicating alignment with shareholders .
    • Governance infrastructure includes charters, ethics, insider trading, clawback policy, and related-party transaction review by the Audit Committee .
  • Monitoring points:
    • External operating roles (CEO of RST Automation; President of Strategic Data Marketing) warrant routine conflict screening, though related-person transaction oversight is established via Audit Committee policy .
  • RED FLAGS: No pledging/hedging of company stock is disclosed in the proxy; insider trading policy applies to directors . No related-person transactions are identified in the cited sections; the Audit Committee reviews any such transactions pursuant to policy .

Appendix: Director Compensation Detail (FY 2024)

NameFees earned or paid in cash ($)Stock awards ($)Option awards ($)Total ($)
Paul A. Seid$45,000$70,925$14,417$130,342

Appendix: Committee Composition (2024 Activity)

CommitteeMembersChairMeetings (2024)
AuditC. D. Allen Jr.; R. L. Baum Jr.; Donna Carroll; D. E. HaileyDouglas E. Hailey4
CompensationC. D. Allen Jr.; R. L. Baum Jr.; Donna Carroll; Paul A. SeidRichard L. Baum Jr.1
Nominating & Corporate GovernanceR. L. Baum Jr.; D. E. Hailey; Paul A. SeidRichard L. Baum Jr.1

Appendix: Board & Annual Meeting Attendance (2024)

  • Board meetings: 5; each director attended all Board meetings and ≥75% of applicable committee meetings .
  • Annual meeting: All seven directors present .